Cite
HARVARD Citation
Paplomata, E. et al. (2018). ABP 980: promising trastuzumab biosimilar for HER2-positive breast cancer. Expert opinion on biological therapy. pp. 335-341. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Paplomata, E. et al. (2018). ABP 980: promising trastuzumab biosimilar for HER2-positive breast cancer. Expert opinion on biological therapy. pp. 335-341. [Online].